Johnson & Johnson (JNJ)vsNutex Health Inc (NUTX)
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
NUTX
Nutex Health Inc
$212.63
+2.10%
HEALTHCARE · Cap: $1.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 11632% more annual revenue ($99.33B vs $846.72M). NUTX leads profitability with a 21.2% profit margin vs 16.2%. NUTX trades at a lower P/E of 8.3x. NUTX earns a higher WallStSmart Score of 63/100 (C+).
JNJ
Buy57
out of 100
Grade: C
NUTX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Margin of Safety
+61.5%
Fair Value
$267.71
Current Price
$212.63
$55.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Strong operational efficiency at 57.8%
Earnings expanding 95.9% YoY
Every $100 of equity generates 28 in profit
Keeps 21 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Smaller company, higher risk/reward
Revenue declined 13.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : NUTX
The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth. Profitability is solid with margins at 21.2% and operating margin at 57.8%.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : NUTX
The primary concerns for NUTX are Market Cap, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NUTX is a declining play — different risk/reward profiles.
NUTX carries more volatility with a beta of 2.00 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
NUTX scores higher overall (63/100 vs 57/100), backed by strong 21.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Nutex Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?